A recent clinical study revealed that the dual SGLT-1/-2 inhibitor sotagliflozin reduces the overall risk of cardiovascular death, HF hospitalization, and emergency HF in patients with type 2 diabetes mellitus and chronic kidney disease (31). This evidence concerns the gene SLC5A1 and hydrops fetalis.